currency icon
Sterling Pound
Australian Dollar
Singapore Dollar
US Dollar
UAE Dirham
Thai Baht
New Zealand Dollar
South Korean won
Indian Rupee
Canadian Dollar
Malaysian Ringgit
South African Rand
Swiss Franc
Czech Koruna
Polish Zloty
Costa Rican Colón
Guatemalan Quetzal
Nicaraguan Córdoba
Panamanian Balboa
Israeli Shekel
Argentine Peso
Brazilian Real
Chilean Peso
Colombian Peso
Peruvian Sol
Mexican Peso
Turkish Lira
Japanese Yen
New Taiwan Dollar
Indonesian Rupiah
Hong Kong Dollar
Romanian Leu
Philippine Peso
Norwegian Krone
Vietnamese Dong
Ukrainian Hryvnia
Russian Ruble
Hungarian Forint
Omani Rial
Swedish Krona
Danish Krone
Egyptian Pound
language icon
phone icon
UK - +44 (0) 20 3871 8666
AU - +61 (0) 2 8311 4096
MY - +60 (0) 3 3099 2504
IN - +91 73 1 485 0222
University of Cambridge Receives a £200,000 Award

University of Cambridge Receives a £200,000 Award

Created At:28 June, 2022
Created By:Casita Team
Updated At:

Share this article:

Under Innovate UK’s Knowledge Transfer Partnership (KTP) programme, 52 North Health and the University of Cambridge have been awarded £200,000 to help in research programmes. The Hauser Forum-based MedTech company 52 North Health is best known for its NeutroCheck device. The NeutroCheck is a low-cost device that’s used for testing suspected neutropenic sepsis at home. Also, the company won the Tech for Good Award at the recent Cambridge Independent Science & Technology Awards 2022. 

The KTP programme, which was founded in 1975, aims to create a connection between forward-thinking businesses and the UK's world-class knowledge bases in order to deliver business-led innovation projects for growth.

This award will mainly fund the creation of a new post for an immunoassay scientist for two and a half years. The scientists will develop and validate new antibodies to create the next generation of low-cost rapid diagnostic solutions. This programme also includes a bespoke residential training project.

The group leader at the Department of Chemistry at the University of Cambridge, Dr Pietro Sormanni, has said: “From an academic standpoint, this partnership represents the unique opportunity to translate the fundamental research we carry out into clinical reality, with the potential to greatly improve the healthcare journey of many patients.”

Subscribe to download